

# INTRODUCTION TO IFPMA AND THEIR ROLE IN GLOBAL HEALTH POLICY

Dr. Mümün Gencoglu

*Regulatory Affairs Manager - International Federation of  
Pharmaceutical Manufacturers & Associations (IFPMA)*

# IFPMA in Brief

## MISSION AND VISION

### VISION

IFPMA is the voice for biopharmaceutical innovation and health progress around the world

### MISSION

To promote policies, dialogues and initiatives that encourage the discovery of and access to medicines and vaccines globally

## WHO WE ARE

### THOUGHT LEADER

Share expertise in key fora about innovation, regulatory and health policy issues

### SOLUTIONS PARTNER

Tackle health challenges responsibly and collaboratively, to improve health outcomes

### CONVENER

Build bridges within and across sectors to advance mutual goals and gain trust

# Bridge between the industry and global health stakeholders

IFPMA is a strong, assertive voice for the industry's value proposition, with a portfolio of constructive initiatives, positioning the industry as thought leaders and solutions partners.



IFPMA brings insights on political and policy trends, and external stakeholder perspectives to its members.

# Interlocutor for intergovernmental organizations

Consultative status with the United Nations:



Engage with other multilateral organizations:




# IFPMA Membership

**IFPMA** is the **industry interlocutor** globally with ~50 associations and ~40 companies in all 5 continents

Europe: 21 Associations

**50**

Associations In  
All 5 Continents



Americas: 11 Associations

Asia Pacific: 15 Associations

Middle East & Africa: 3 Associations

# Industry membership

abbvie



AMGEN



AstraZeneca



Chiesi



Lilly



Johnson & Johnson




MERCK




NOVARTIS



# IFPMA strategic priorities



# Pharmaceutical Innovation: A long and complex process




IFPMA (2012) The New Frontiers of Biopharmaceutical Innovation. Geneva: International Federation of Pharmaceutical Manufacturers & Associations, p 9. [http://www.ifpma.org/fileadmin/content/Publication/2013/IFPMA\\_Incremental\\_Innovation\\_Feb\\_2013\\_Low-Res.pdf](http://www.ifpma.org/fileadmin/content/Publication/2013/IFPMA_Incremental_Innovation_Feb_2013_Low-Res.pdf)



# Pharmaceutical industry investment in R&D

**1,000,000,000** CHF investment  
**7,000,874** hours of work  
**6,587** experiments  
**423** researchers  
**1** drug



European Commission (2015) The 2015 EU Industrial R&D Investment Scoreboard; p50.  
<http://iri.jrc.ec.europa.eu/scoreboard15.html>


# Innovative Medicines: pushing the limits of science with a vibrant pipeline



IFPMA (2017), The Pharmaceutical Industry and Global Health: Facts and Figures 2017. PhRMA (2016) Chart Pack Biopharmaceuticals in Perspective. Washington DC: Pharmaceutical Research and Manufacturers of America, p 22.

# IFPMA is advocating for better access to advanced therapies

## Growth Projections for Cell and Gene Therapy Market



1 *Regenerative Medicines Market: Global Opportunity Analysis and Industry Forecast, 2015–2022*. Allied Market Research: Pune, Maharashtra, India: August 2016; [www.alliedmarketresearch.com/regenerative-medicines-market](http://www.alliedmarketresearch.com/regenerative-medicines-market).

2 Chartrain NA, Williams CB, Whittington AR. Engineering Tissues with Bioprinting. *BioProcess Int.* 14(10) 2016: 28–33.

# Building Solutions and forming strategic alliances are a key priority for IFPMA

Drive alliance-building programs with other industries and key opinion leaders



Create a cross-industry coalition of innovative industries



Build a "Health Partners Forum"



Engage with tomorrows' leaders





**IFPMA**

**Learn more and  
stay connected**



[www.ifpma.org](http://www.ifpma.org)

